Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$129.93 USD

129.93
5,633,889

+2.64 (2.07%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $129.95 +0.02 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates

by Zacks Equity Research

STERIS (STE) continues to gain from strength in all business segments in Q3.

Zacks Equity Research

Here's Why Momentum Investors Will Love Abbott (ABT)

by Zacks Equity Research

Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

IRADIMED (IRMD) reports growth across all operating segments and geographies

Zacks Equity Research

Here's Why You Should Buy Wright Medical (WMGI) Stock Now

by Zacks Equity Research

A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for February 11th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 11th:

Zacks Equity Research

Phirbo (PAHC) Q2 Earnings Lag Estimates, Operating Margin Up

by Zacks Equity Research

Phirbo (PAHC) witnesses significant growth in core segment revenues in Q2.

Zacks Equity Research

Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.

Zacks Equity Research

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.

Zacks Equity Research

Here's Why You Should Invest in McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson's (MCK) solid prospects in the pharmaceutical and medical supplies distribution market look promising.

Zacks Equity Research

Here's Why You Should Hold Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical's (ISRG) solid exposure to robotics & medical mechatronics is commendable. Its robot-based da Vinci Surgical System for minimally-invasive surgery is an added positive.

Zacks Equity Research

Surmodics (SRDX) Q1 Earnings & Revenues Beat, Guidance Solid

by Zacks Equity Research

Surmodics' (SRDX) fiscal Q1 sees solid contributions from all segments.

Zacks Equity Research

Abbott (ABT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $69.69, moving +0.93% from the previous trading session.

Zacks Equity Research

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.

Zacks Equity Research

Abbott (ABT) Upgraded to Buy: Here's Why

by Zacks Equity Research

Abbott (ABT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Company News For Jan 24, 2019

by Zacks Equity Research

Companies In The News Are: KMB,ABT,SYF,WMT,QSR

Zacks Equity Research

Abbott (ABT) Q4 Earnings Meet Estimates, Organic Growth Solid

by Zacks Equity Research

Within Structural Heart, growth is driven by several product areas across Abbott's (ABT) broad portfolio.

Zacks Equity Research

Abbott (ABT) Meets Q4 Earnings Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 0.00% and -0.29%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Medical Product Stocks' Earnings on Jan 23: ABT, NXGN & VAR

by Zacks Equity Research

Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.

Zacks Equity Research

Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?

by Zacks Equity Research

Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.

Zacks Equity Research

Is a Surprise Coming for Abbott (ABT) This Earnings Season?

by Zacks Equity Research

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

What Lies Ahead for Abbott (ABT) Stock This Earnings Season?

by Zacks Equity Research

Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.

Sreyoshi Mukherjee headshot

3 Weight-Loss Stocks in Focus on Rising Obesity Fears

by Sreyoshi Mukherjee

Three companies with bright prospects as the U.S. weight-loss industry keeps up its battle against obesity.

Zacks Equity Research

Abbott (ABT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Abbott (ABT) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $68.27, marking a -1.53% move from the previous day.

Zacks Equity Research

Zacks Value Trader Highlights: PayPal, Abbott Labs, UnitedHealth, Lam Research and Visa

by Zacks Equity Research

Zacks Value Trader Highlights: PayPal, Abbott Labs, UnitedHealth, Lam Research and Visa